| Name | Title | Contact Details |
|---|
Liquidia Technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles.
We are harnessing the #gut brain axis & the #CNS to develop a new class of therapeutics for people with neurological diseases & disorders
At Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the gut informs our brains about our well-being, metabolism, and nutritional state. The gut-brain axis—the communication highway between our gut and our brain—offers an unprecedented opportunity to access and influence brain centers involved in fundamental human processes. An understanding of the biology mediated by the gut and gut-brain circuits will change the way we think about food, nutrition, and human physiology. Founded and headquartered in New York City, we are developing an industry-leading platform to harness the gut-brain axis. Our cross-disciplinary biotechnology team will integrate cutting-edge technologies in sequencing, bioinformatics, neural imaging, cellular and molecular biology, and human genetics to provide an understanding of gut-brain biology that will lead to transformational therapeutics and consumer products to improve human health and nutrition.
Gotham Therapeutics has assembled an exceptional team and network to establish a novel drug class targeting RNA-modifying proteins.
CARIS MPI is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.